UCB selected Gwinnett County, Georgia, as the site for its new U.S. biologics manufacturing facility, projecting a $2 billion investment for a 460,000-square-foot campus. The site is designed to produce complex biologics 24/7 for the U.S. market and expand UCB’s supply resilience. UCB said the facility will use a digital-first approach featuring AI, robotics, and automation, aiming to improve throughput and operational control across its biologics pipeline. The company framed the move as strengthening U.S.-based manufacturing capabilities amid continued regulatory and demand pressures. The company estimates the project’s economic impact at approximately $5 billion and described the campus as a cornerstone of its global biologics manufacturing network.